Predicting recurrence in oral cavity cancers: a review of 116 patients with buccal mucosa carcinoma in northwestern India

Article information

Arch Craniofac Surg. 2023;24(5):211-217
Publication date (electronic) : 2023 October 20
doi : https://doi.org/10.7181/acfs.2023.00311
Department of Surgical Oncology, Sawai Man Singh Medical College, Jaipur, India
Correspondence: Pranav Mohan Singhal Department of Surgical Oncology, Sawai Man Singh Medical College, 601, 6th Floor, Marble House, B-82, Rajendra Marg, Bapu Nagar, Jaipur 302004, India E-mail: 06.pranav@gmail.com
Received 2023 June 16; Revised 2023 July 18; Accepted 2023 September 11.

Abstract

Background

Oral cavity cancers, the second most common type in India, are responsible for 10% of the overall cancer burden. With a recurrence rate of 30% to 40% and a 5-year survival rate of 50%, these malignancies account for substantial morbidity and mortality. Despite advances in treatment modalities, survival rates following treatment completion have not improved significantly. The present study aimed to establish specific epidemiological and pathological factors responsible for recurrence after treatment completion in buccal mucosa cancers.

Methods

A retrospective analysis of the data of 116 patients treated for biopsy-proven cancers of the buccal mucosa was undertaken 1 year after treatment completion. Factors such as age, sex, education, lymphovascular invasion, extranodal extension (ENE), perineural invasion, depth of invasion, and pathological margin status were compared between patients who presented with recurrence and those who did not. Statistical significance was set at p< 0.05.

Results

Of the 116 patients, 40 (34.5%) developed a recurrent disease within 1 year. The mean age of the study population was 43.3 years, and males constituted 91.4% of the included patients. Ipsilateral buccal mucosa was the commonest site of disease recurrence. Neck node metastasis, ENE, and margins of resection < 5 mm were significantly related to the recurrence of disease. However, surprisingly, lymphovascular invasion, perineural invasion, and depth of invasion > 10 mm did not show statistically significant associations.

Conclusion

Neck node metastasis, ENE, and margins of resection < 5 mm were the histopathological factors associated with recurrence in cancers of the buccal mucosa.

INTRODUCTION

Lip and oral cavity cancers pose an enormous burden on the Indian healthcare system. Accounting for 10.3% of the overall cancer cases in India, these malignancies are the second most common cancers diagnosed after breast malignancies and the third most common cause of cancer-related mortality after cancers of the breast and cervix [1].

With a cumulative 5-year survival rate of around 50%, which decreases to 30% in advanced presentations, these cancers are responsible for substantial morbidity and mortality [2]. Advances in treatment modalities, including the use of adjuvant chemoradiotherapy have not led to a significant improvement in survival in oral squamous cell carcinoma (OSCC) [3]. Locoregional recurrence (LRR) is seen in 10% to 30% of patients following treatment completion and is generally considered to be a predictor of an unfavorable prognosis regarding survival [4,5]. Despite the massive impact of recurrence on OSCC prognosis, we have only a limited understanding of the patterns and factors responsible for recurrence [3,6]. This can be attributed to the diverse nature of studies done previously, varying treatment strategies, and the fact that squamous cell carcinomas (SCCs) arising in different subsites of the oral cavity are distinct entities. The absence of specific biomarkers to predict each patient’s disease burden not only hinders our provision of effective treatment plans, but also leads to deficiencies in monitoring for recurrence [7].

The present retrospective observational study aimed to analyze the epidemiological and clinicopathological features associated with LRR in OSCC of the buccal mucosa (BM).

METHODS

Study design and place

The present study was conducted in the Department of Surgical Oncology, Sawai Man Singh Medical College, Jaipur, Rajasthan, India after clearance was obtained from the institutional ethics committee. Reports of 116 biopsy-proven cases of OSCC of BM diagnosed and treated between January 2020 and June 2021 were analyzed retrospectively. Data was collected and analyzed from the medical records department and outpatient documentation 1 year after completion of treatment.

The inclusion criteria for this study were as follows: (1) patients with biopsy-proven OSCC of BM; (2) patients aged >18 years; or (3) patients who completed treatment according to institutional protocols. Exclusion criteria for patients were as follows: (1) patients with SCC of another site of the oral cavity, such as the tongue or hard/soft palate; (2) patients presenting with a recurrence or distant metastasis; (3) patients who received a form of anti-cancer therapy previously, including surgery, chemotherapy, or radiotherapy; (4) those with positive surgical margins; or (5) those who were lost to follow-up or who did not complete treatment according to institutional protocols.

Treatment

All patients with biopsy-proven OSCC of BM were staged using contrast-enhanced computed tomography (CECT) scans of the face and neck, as well as a CECT chest scan to detect lung metastasis. All patients underwent a wide local excision of the primary carcinoma, including a segmental/marginal mandibulectomy (if needed) with neck dissection from levels 1 to 5 according to institutional protocols. Reconstruction was done using a pectoralis major myocutaneous flap, nasolabial flap, or free flap. The pathological stage was assigned postoperatively according to the eighth edition of the American Joint Committee on Cancer (AJCC) TNM classification [8]. Patients with positive neck node metastasis, T3/T4 stage disease, perineural invasion (PNI), depth of invasion (DOI) >5 mm, and closest margin of resection <5 mm received adjuvant treatment in the form of postoperative radiotherapy at a dose of 60 Gy to the tumor bed and ipsilateral neck. Those with extranodal extension (ENE) received additional chemotherapy in the form of carboplatin and paclitaxel for six cycles. Patients with positive margins were excluded from the study.

Follow-up

Follow-up occurred three times at 1-month intervals. A thorough physical examination was conducted along with a chest X-ray. Patients presenting with suspicion of recurrence underwent a CECT scan of the face and neck along with a CECT scan of the chest. Suspicious lesions were biopsied.

Statistical analysis

We investigated the following factors: age, sex, pathological stage, tumor (T) stage, nodal (N) stage, DOI, PNI, lymphovascular invasion (LVI), ENE, and closest margin of resection. The relationship of these factors with the recurrence of OSCC was established by comparing the data of those who had recurrences and those who did not. Statistical analysis was undertaken using SPSS version 23.0 (IBM Corp.). The prognostic significance of DOI and pathological margins was calculated at various cutoff values. Univariate and multivariate analyses were used to identify the independent risk factors for LRR. The chi-square test was used for the univariate analysis, and multivariate analysis of the prognostic factors was performed using the Cox logistic regression method. In all analyses, p<0.05 was considered significant.

RESULTS

The present study included 116 patients who underwent wide local excision and neck dissection, followed by reconstruction using a pedicled flap or a free flap, to manage OSCC of BM between January 2020 and June 2021. Adjuvant therapy in the form of radiotherapy or chemoradiotherapy was administered if indicated. Analyses took place 1 year after the completion of treatment. Forty patients (34.5%) exhibited recurrence and 76 patients (65.5%) were disease-free at 1 year after treatment completion. Among the 40 patients who developed recurrence, 25 (62.5%) were diagnosed within the first 6 months of treatment completion, and the other 15 cases (37.5%) were detected at the 1-year follow-up.

Males constituted 91.4% of the study population, with 106 cases, whereas females were affected in 10 cases (8.7%). Of the 116 patients, 79 (68.1%) were younger than 50 years, and 37 patients (31.9%) were aged 50 years or older at the time of primary presentation. Compared to the 109 patients (93.96%) who admitted to a regular tobacco chewing habit, only 51 patients (43.96%) admitted to a regular habit of smoking cigarettes or bidis. Although only a small number of patients (n=11, 9.5%) had not received any formal education, we found a statistically significant relationship (p=0.034) between the absence of formal education and development of LRR (Table 1).

Epidemiological analysis of the study population

The most common site of disease recurrence was the ipsilateral BM with 20 cases (50%). The ipsilateral neck was affected in 10 cases (25%), and the tongue was the site of recurrence in four cases (10%). In three patients (7.5%), recurrences developed on the pectoralis major myocutaneous flap used to reconstruct the defect. Contralateral BM was affected in three cases (7.5%).

On histopathological analysis, 99 patients (85.3%) presented with a moderately differentiated carcinoma, the commonest variety found in both the recurrence and non-recurrence groups. Interestingly, most patients in the recurrence group presented with a T2 disease (18 cases, 45%), followed by a T3 disease (17 cases, 42.5%). T4 disease was seen in only five patients (12.5%) in the recurrence group. In the group of patients presenting without recurrence, T4 was the commonest presentation (35 patients, 46.1%), followed by T3 disease with 20 patients (26.3%) (Table 2).

Comparison of histopathological features between patients with and without recurrence of oral cavity cancers

The present study found a significant correlation between neck node metastasis and development of LRR (p<0.001). N1 disease in 14 patients (35%) formed the commonest nodal presentation in the recurrence group; it is important to note that 12 patients (30%) in the recurrence group presented with ENE. In the group without recurrence, a pathologically uninvolved neck (N0) was the commonest presentation, with 47 cases (61.8%). Only six patients (7.9%) in this group had ENE, which also had a statistically significant impact on development of LRR (p=0.002) (Table 2).

Among the 116 cases included in our study, PNI and LVI were seen in only five cases (4.3%) and 11 cases (9.5%), respectively. Although higher rates of PNI and LVI were reported in the recurrence group, a statistically significant association between LRR and either PNI or LVI could not be determined (p>0.05).

To our surprise, patients in the non-recurrence group had more tumors with a deeper tumor penetration than those in the recurrence group. Forty (52.5%) of the 76 patients who did not develop a recurrence had a DOI >10 mm, whereas only 15 patients (37.5%) of the 40 patients reporting recurrence had a DOI >10 mm. The present study could not establish a statistically significant relationship between a larger DOI and LRR.

A significant association was seen between development of LRR and margins of resection that were less than 5 mm. Of the 40 patients presenting with recurrence, 24 patients (60%) had their closest margin of resection less than 5 mm, in contrast to only 27 patients (35.5%) in the non-recurrence group. The relationship between recurrence and the closest margin of resection being less than 5 mm was statistically significant (p=0.012) (Table 2).

DISCUSSION

Limited awareness of OSCC as a disease with substantial morbidity and mortality leads to patients visiting oncology clinics only when a growth inside the mouth fails to regress with time or is substantially painful.

Although 1 year of follow-up is a relatively short time to comment on recurrences in oral cavity cancers, as a tertiary care center in India, we deal mainly with advanced cases. Most of our patients who experience recurrence present within a year of treatment completion. Therefore, this analysis was performed at 1 year.

Men were predominantly affected in our study, accounting for 91.4% (106 cases) of the study population. Other reports from our region and other areas in the Indian subcontinent supported this trend of higher prevalence of OSCC in males [9-11]. Although the majority of patients in the Western world with oral cavity cancers present at an older age [12,13], the mean age of patients in our study was 43.3 years. Overall, 68% of our study population was younger than 50 years of age. Other studies from in and around India also reported a trend of younger patients presenting with oral cavity cancers [9,10]. Although two studies from Iran found a statistically significant relationship among a younger age of disease presentation, LRR, and survival [14,15], the present study could not establish such a correlation. Younger age of disease presentation and higher prevalence of OSCC in males in our study can be attributed to the rampant tobacco chewing behavior of young males in our region and a possibility of continuation of the habit even after undergoing treatment for OSCC, which might contribute to recurrence [16]. Many studies from around the world have concluded that the risk of LRR increases with age [12,13]. Increased duration of exposure to tobacco and other carcinogens may support more presentations and an increased incidence of recurrence in older age [17].

We found a statistically significant relationship between the absence of formal education and the incidence of recurrence in our population. Although only 11 patients (9.48%) in our study had not received formal education, a significantly higher proportion of patients in the group with recurrence had not received formal education compared to the group without recurrence (17.5% vs. 5.2%, respectively). The educated patients may have been more concerned about their ailment and attended their follow-up visits consistently. They probably avoided tobacco in any form posttreatment. We could not find any other previous literature to corroborate or dispute this finding.

Our study could not establish significance regarding the impact of higher T-stages on LRR. To our surprise, a higher T-stage was reported in more patients without recurrence than in those whose cancers recurred. In a meta-analysis on margin size and disease recurrence, Anderson et al. [18] asserted that the recurrence rates were similar between T1/T2 and T3/T4 groups. Other studies also failed to demonstrate the importance of an advanced T-stage for LRR [11,19,20].

We found a significant association between neck node metastasis and the development of recurrence whose significance was maintained in the multivariate analysis. The impact of pathologically involved nodes on recurrence has been documented by several studies from around the world [19,21,22]. Kartini et al. [15] reported that patients in Indonesia with N2 disease had a 1.4-fold higher risk of mortality than N0 patients. Several researchers have also reported an association between LRR and ENE [22,23]. Other studies, including a 2015 study from the Memorial Sloan Kettering Cancer Center, stated that the spread of disease 1.7 mm beyond the nodal capsule was associated with lower odds of disease-free survival after treatment [24,25]. We found ENE to be significantly associated with recurrence in the univariate analysis, but not in the multivariate analysis.

While the impact of tumor differentiation on LRR has been documented by several researchers [26,27], neither our study nor several others have established a significant relationship between tumor differentiation and prognosis [11,20]. It is important to note that moderately differentiated tumors affected more than 80% of the patients in both the recurrence and nonrecurrence groups in our study.

The inclusion of DOI in the new AJCC staging system for oral cavity malignancies demonstrates its significance in determining the prognosis of these tumors [8]. Many reports have documented a worse chance of disease-free survival as the DOI increases, especially to more than 10 mm [21,22]. The present study could not establish a significant impact of a DOI of more than 10 mm on LRR. To our surprise, though only 37.5% of the patients who developed recurrence had a DOI >10 mm, 52.5% of the patients who did not develop recurrence within 1 year of treatment completion had a DOI >10 mm.

Our study also could not establish any significant impact of PNI and LVI on LRR. Several studies, including that of Abbas et al. in Karachi [11], successfully established the significance of these factors for LRR [19,22]. Interestingly, Marinelli et al. [13] reported that PNI and LVI had an impact on overall survival but could not establish their role in LRR. Marzouki et al. [20] determined that PNI had a significant impact on LRR, whereas LVI was not found to have a statistically significant relationship with LRR.

Our study’s small sample size and its follow-up period of only 1 year could be responsible for the inability to demonstrate the effects of PNI and LVI on LRR in oral cavity cancers.

Apart from pathologically proven neck node metastasis, the only factor identified in the multivariate analysis as having a statistically significant relationship with LRR was the closest margin of resection measuring less than 5 mm. The width of the margins is of importance because epithelial dysplasia has been found near the surgical margins and can be an important cause of recurrence in patients not receiving adjuvant therapy [18]. Anderson et al. [18] and Carrillo et al. [19] also concluded that margins less than 5 mm had a greater risk of LRR. A few studies have questioned the impact of margins on the overall prognosis [5,20]. Abbas et al. [11] observed that although a positive margin was not associated with a poorer outcome, close margins were associated with a higher incidence of recurrence. These varying results could probably be explained by the uneven distribution of tumor sites and the impact of adjuvant therapy in patients with close or positive margins. Despite receiving adjuvant radiation, patients with close margins in our study had a significant association with recurrence. Adjuvant therapy probably did not have much of an impact in preventing recurrences in patients with close margins <5 mm.

The limitations of this study include its retrospective design with a relatively small sample size. We were not able to document the continued tobacco/betel nut chewing and smoking habits of our patients posttreatment. Another factor that could have impacted the results and was not assessed was the interval between surgery and the start of adjuvant treatment.

The present retrospective study found that the histopathological factors responsible for recurrence in patients presenting with OSCC were neck node metastasis, ENE, and close margins of resection during the primary surgery. Important factors established in previously conducted studies, such as PNI, LVI, DOI >10 mm, and an advanced T-stage, failed to show statistically significant associations with LRR in our study. It is incumbent upon us to recognize factors responsible for and predictive of recurrence. Aggressive treatment with early recognition of locoregional and distant failures will go a long way in increasing survival rates for OSCC. A study involving a greater number of patients with a prolonged follow-up will help us determine which factors are not only responsible for LRR but relevant to overall survival.

Notes

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Funding

None.

Ethical approval

The study was approved by the Sawai Man Singh Medical College of Ethics Committee (No. 101/MC/2023) and performed in accordance with the principles of the Declaration of Helsinki. The informed consent was waived because this study design is a retrospective chart review.

Author contributions

Conceptualization: Pinakin Patel, Pranav Mohan Singhal, Kamal Kishor Lakhera. Data curation: Agil Babu. Formal analysis: Pinakin Patel, Pranav Mohan Singhal, Kamal Kishor Lakhera, Agil Babu, Suresh Singh, Naina Kumar Agarwal. Methodology: Pinakin Patel, Pranav Mohan Singhal, Aishwarya Chatterjee, Agil Babu, Shubhra Sharmas. Project administration: Pinakin Patel, Pranav Mohan Singhal, Suresh Singh, Naina Kumar Agarwal, Shubhra Sharmas. Visualization: Pranav Mohan Singhal. Writing - original draft: Pinakin Patel, Pranav Mohan Singhal, Kamal Kishor Lakhera, Bhoopendra Singh Gora. Writing - review & editing: Pinakin Patel, Pranav Mohan Singhal, Aishwarya Chatterjee. Investigation: Pinakin Patel, Pranav Mohan Singhal, Kamal Kishor Lakhera, Aishwarya Chatterjee, Agil Babu. Resources: Pinakin Patel, Pranav Mohan Singhal, Aishwarya Chatterjee, Suresh Singh, Bhoopendra Singh Gora, Shubhra Sharmas. Supervision: Pinakin Patel, Pranav Mohan Singhal, Kamal Kishor Lakhera, Suresh Singh, Bhoopendra Singh Gora. Validation: Pinakin Patel, Pranav Mohan Singhal, Kamal Kishor Lakhera, Shubhra Sharmas.

Abbreviations

AJCC

American Joint Committee on Cancer

BM

buccal mucosa

CECT

contrast-enhanced computed tomography

DOI

depth of invasion

ENE

extranodal extension

LRR

locoregional recurrence

LVI

lymphovascular invasion

OSCC

oral squamous cell carcinoma

PNI

perineural invasion

SCC

squamous cell carcinoma

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
2. Chinn SB, Myers JN. Oral cavity carcinoma: current management, controversies, and future directions. J Clin Oncol 2015;33:3269–76.
3. Safi AF, Kauke M, Grandoch A, Nickenig HJ, Zoller JE, Kreppel M. Analysis of clinicopathological risk factors for locoregional recurrence of oral squamous cell carcinoma: retrospective analysis of 517 patients. J Craniomaxillofac Surg 2017;45:1749–53.
4. Vikram B, Strong EW, Shah JP, Spiro R. Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg 1984;6:720–3.
5. Brandwein-Gensler M, Teixeira MS, Lewis CM, Lee B, Rolnitzky L, Hille JJ, et al. Oral squamous cell carcinoma: histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. Am J Surg Pathol 2005;29:167–78.
6. Safi AF, Grandoch A, Nickenig HJ, Zoller JE, Kreppel M. The importance of lymph node ratio for locoregional recurrence of squamous cell carcinoma of the tongue. J Craniomaxillofac Surg 2017;45:1058–61.
7. Thakur R, Thakar A, Malhotra RK, Sharma A, Kakkar A. Tumor-host interface in oral squamous cell carcinoma: impact on nodal metastasis and prognosis. Eur Arch Otorhinolaryngol 2021;278:5029–39.
8. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67:93–9.
9. Sharma RG, Bang B, Verma H, Mehta JM. Profile of oral squamous cell cancer in a tertiary level medical college hospital: a 10 yr study. Indian J Surg Oncol 2012;3:250–4.
10. Aggarwal VP, Rao DCL, Mathur A, Batra M, Makkar DK. Prevalence of head and neck and oral cancer in rajasthan: an infirmary based retrospective study. Clin Cancer Investig J 2015;4:339–43.
11. Abbas SA, Saeed J, Tariq MU, Baksh AR, Hashmi S. Clinicopathological prognostic factors of oral squamous cell carcinoma: an experience of a tertiary care hospital. J Pak Med Assoc 2018;68:1115–9.
12. Sundermann BV, Uhlmann L, Hoffmann J, Freier K, Thiele OC. The localization and risk factors of squamous cell carcinoma in the oral cavity: a retrospective study of 1501 cases. J Craniomaxillofac Surg 2018;46:177–82.
13. Marinelli LM, Chatzopoulos K, Marinelli JP, Chen TY, Collins AR, Sotiriou S, et al. Clinicopathologic predictors of survival in buccal squamous cell carcinoma. J Oral Pathol Med 2020;49:857–64.
14. Taghavi N, Yazdi I. Prognostic factors of survival rate in oral squamous cell carcinoma: clinical, histologic, genetic and molecular concepts. Arch Iran Med 2015;18:314–9.
15. Kartini D, Kurnia A, Putri SR, Thaher TC, Handjari DR, Khoe LC, et al. Survival rate and prognostic factors of oral squamous cell carcinoma in Indonesia: a single-center retrospective study. Forum Clin Oncol 2022;13:15–22.
16. Grover S, Anand T, Kishore J, Tripathy JP, Sinha DN. Tobacco use among the youth in India: evidence from global adult tobacco survey-2 (2016-2017). Tob Use Insights 2020;13:117917–3. X20927397.
17. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg 2003;61:751–8.
18. Anderson CR, Sisson K, Moncrieff M. A meta-analysis of margin size and local recurrence in oral squamous cell carcinoma. Oral Oncol 2015;51:464–9.
19. Carrillo JF, Carrillo LC, Cano A, Ramirez-Ortega MC, Chanona JG, Aviles A, et al. Retrospective cohort study of prognostic factors in patients with oral cavity and oropharyngeal squamous cell carcinoma. Head Neck 2016;38:536–41.
20. Marzouki HZ, Bukhari AF, Al-Ghamdi DA, Abdullah RM, Al-Hajeili M, Khayyat S, et al. Worst pattern of invasion and other histopathological features in oral cancer as determinants of prognosis and survival rate: a retrospective cohort analysis. Oncol Lett 2023;25:75.
21. Liao CT, Chang JT, Wang HM, Ng SH, Hsueh C, Lee LY, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol 2008;15:915–22.
22. Dolens ED, Dourado MR, Almangush A, Salo TA, Gurgel Rocha CA, da Silva SD, et al. The impact of histopathological features on the prognosis of oral squamous cell carcinoma: a comprehensive review and meta-analysis. Front Oncol 2021;11:784924.
23. Shaw RJ, Lowe D, Woolgar JA, Brown JS, Vaughan ED, Evans C, et al. Extracapsular spread in oral squamous cell carcinoma. Head Neck 2010;32:714–22.
24. Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gonen M, et al. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. Head Neck 2016;38 Suppl 1:E1192–9.
25. Kwon M, Roh JL, Lee J, Cho KJ, Choi SH, Nam SY, et al. Extranodal extension and thickness of metastatic lymph node as a significant prognostic marker of recurrence and survival in head and neck squamous cell carcinoma. J Craniomaxillofac Surg 2015;43:769–78.
26. Fan KH, Lin CY, Kang CJ, Lee LY, Huang SF, Liao CT, et al. Postoperative concomitant chemoradiotherapy improved treatment outcomes of patients with oral cavity cancer with multiple-node metastases but no other major risk factors. PLoS One 2014;9e86922.
27. Troeltzsch M, Haidari S, Boser S, Troeltzsch M, Probst FA, Ehrenfeld M, et al. What factors are associated with regional recurrence after operative treatment of oral squamous cell carcinoma? J Oral Maxillofac Surg 2018;76:2650–9.

Article information Continued

Table 1.

Epidemiological analysis of the study population

Epidemiological factors assessed Cases with recurrence (n = 40) Cases without recurrence (n = 76) p-value
Sex 0.701
 Male 36 (90.0) 70 (92.1)
 Female 4 (10.0) 6 (7.9)
Age 0.248
 ≤ 50 yr 30 (75.0) 49 (64.5)
 > 50 yr 10 (25.0) 27 (35.5)
Smoker 0.179
 Yes 21 (52.5) 30 (39.5)
 No 19 (47.5) 46 (60.5)
Tabacco chewer 0.064
 Yes 35 (87.5) 74 (97.4)
 No 5 (12.5) 2 (2.6)
Education 0.034
 No formal 7 (17.5) 4 (5.2)
 School and above 33 (82.5) 72 (94.8)

Values are presented as number (%).

Table 2.

Comparison of histopathological features between patients with and without recurrence of oral cavity cancers

Histopathological variable Cases with recurrence (n = 40) Cases without recurrence (n = 76) p-value
Grade of tumor 0.957
 Well differentiated 6 (15.0) 8 (10.5)
 Moderately differentiated 33 (82.5) 63 (82.9)
 Poorly differentiated 1 (2.5) 5 (6.6)
Pathological tumor stage 0.060
 T1 0 3 (3.9)
 T2 18 (45.0) 18 (23.7)
 T3 17 (42.5) 20 (26.3)
 T4A 5 (12.5) 35 (46.1)
Pathological node stage < 0.001
 N0 9 (22.5) 47 (61.8)
 N1 14 (35.0) 15 (19.7)
 N2A 2 (5.0) 3 (3.9)
 N2B 3 (7.5) 5 (6.6)
 N3B 12 (30.0) 6 (7.9)
Extranodal extension 0.002
 Yes 12 (30.0) 6 (7.9)
 No 28 (70.0) 70 (92.1)
Perineural invasion 0.220
 Yes 3 (7.5) 2 (2.6)
 No 37 (92.5) 74 (97.4)
Lymphovascular invasion 0.141
 Yes 6 (15.0) 5 (6.6)
 No 34 (85.0) 71 (93.4)
Depth of invasion 0.121
 ≤ 10 mm 25 (62.5) 36 (47.5)
 > 10 mm 15 (37.5) 40 (52.5)
Closest margin of resection 0.012
 ≤ 5 mm 24 (60.0) 27 (35.5)
 > 5 mm 16 (40.0) 49 (64.5)

Values are presented as number (%).